MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.130
-0.040
-3.42%
Closed 17:43 07/22 EDT
OPEN
1.190
PREV CLOSE
1.170
HIGH
1.190
LOW
1.120
VOLUME
107.61K
TURNOVER
0
52 WEEK HIGH
2.120
52 WEEK LOW
0.6501
MARKET CAP
84.45M
P/E (TTM)
-2.0810
1D
5D
1M
3M
1Y
5Y
1D
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
Clearside Biomedical, Inc. Has opened registration for its virtual key opinion leader event on July 24, 2024. The company is revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The event will be held in Atlanta, Georgia.
Barchart · 1d ago
Weekly Report: what happened at CLSD last week (0715-0719)?
Weekly Report · 1d ago
Weekly Report: what happened at CLSD last week (0708-0712)?
Weekly Report · 07/15 09:51
CLEARSIDE BIOMEDICAL APPOINTS DR. GLENN YIU TO ITS SCIENTIFIC ADVISORY BOARD
Reuters · 07/11 11:05
Weekly Report: what happened at CLSD last week (0701-0705)?
Weekly Report · 07/08 09:52
Weekly Report: what happened at CLSD last week (0624-0628)?
Weekly Report · 07/01 09:52
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
Barchart · 06/27 06:05
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD) The company is focused on delivering therapies to the back of the eye through the suprachoroidal space. The analyst sees an opportunity for meaningful appreciation in the company's shares.
Benzinga · 06/25 16:54
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Webull offers Clearside Biomedical Inc stock information, including NASDAQ: CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.